Sector Update: Healthcare; Valeant Unit Wins U.S. FDA Approval for Jublia Nail Infection Treatment
Healthcare stocks were generally lower in afternoon trading, with the S&P/TSX Healthcare index slipping 0.4%.
Valeant Pharmaceuticals (VRX.TO): -0.7%
Tekmira Pharmaceuticals (TKM.TO): +8.4%
Catamaran (CCT.TO): -0.5%
Oncolytics Biotech (ONC.TO): +3.5%
Cardiome Pharma (COM.TO): -0.4%
In corporate news, Valeant Pharmaceuticals Monday said its Valeant Pharmaceuticals North America subsidiary has received U.S. FDA approval for Jublia, the first of its kind for the treatment of nail infection (onychomycosis). The drug maker said Jublia was acquired through the purchase of Dow Pharmaceutical Sciences in 2008. It has advanced Jublia from pre-IND stage through clinical phases 1, 2, and 3 since then.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.